CPHI · China Pharma Holdings, Inc. · Executive Compensation
$0.57
+0.04 (+7.53%)
At close · Nov 6
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As of June 30, 2026, the Company had cash and cash equivalents of $0.3 million and an accumulated deficit of $49.8 million, and the Company's current liabilities exceeded current assets by $5.7 million. In addition, the Company incurred net losses of $2.6 million and had cash outflows from operating activities of $0.08 million for the six months ended June 30, 2026.”View the 10-Q filed Aug 14, 2026
Market Cap
$22.80M
Shares
43.02M
Volume · Nov 6
41.45K
Avg daily vol (3M)
1.81M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Zhilin Li | Chairman, Chief Executive Officer President and interim Chief Financial Officer | $241,600 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Zhilin Li | Chairman, Chief Executive Officer President and interim Chief Financial Officer | $241,600 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Zhilin Li | Chairman, Chief Executive Officer President and interim Chief Financial Officer | $241,600 |
Leadership
- Zhilin Li CEO
- Baowen Dong Board Member
- Gene Michael Bennett Board Member
- Yingwen Zhang Board Member